Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of multiple myeloma
3.2.1.2 Improved diagnostic technologies
3.2.1.3 Patient awareness and education
3.2.2 Industry pitfalls & challenges
3.2.2.1 High treatment costs
3.2.2.2 Adverse effects associated with treatment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Future market trends
3.7 Porter's analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Chemotherapy
5.3 Targeted therapy
5.4 Immunomodulating agents
5.5 Stem cell transplantation
5.6 Radiation therapy
5.7 Other treatment types
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Oral
6.3 Parenteral
Chapter 7 Market Estimates and Forecast, By Disease Type, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Active multiple myeloma
7.3 Smoldering multiple myeloma
Chapter 8 Market Estimates and Forecast, By End-use, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospitals
8.3 Specialty clinics
8.4 Homecare settings
8.5 Other end-users
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Service Provider
10.1.1 Cleveland Clinic
10.1.2 Dana-Farber Cancer Institute, Inc.
10.1.3 Mayo Foundation for Medical Education and Research (MFMER)
10.1.4 MD Anderson Cancer Center
10.1.5 Memorial Sloan Kettering Cancer Center
10.2 Medication Manufacturers
10.2.1 AbbVie Inc.
10.2.2 Amgen Inc.
10.2.3 Bristol-Myers Squibb Company.
10.2.4 Glenmark Pharmaceuticals Ltd.
10.2.5 Johnson & Johnson Services, Inc
10.2.6 Merck & Co, Inc.
10.2.7 Novartis AG
10.2.8 Sanofi S.A.
10.2.9 Takeda Pharmaceutical Company Limited
